Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

(2013) J. Bellmunt et al.   ANNALS OF ONCOLOGY

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

(2013) Gregory R. Pond et al.   BJU INTERNATIONAL

A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors

(2013) Robin L. Jones et al.   INVESTIGATIONAL NEW DRUGS

Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer

(2013) Lainie P. Martin et al.   MEDICAL ONCOLOGY

Metastatic bladder cancer

(2013) Fabio Calabrò et al.   Current Opinion in Supportive and Palliative Care

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches

(2013) Richard M. Bambury et al.   Frontiers in Pharmacology

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

(2012) T A Yap et al.   BRITISH JOURNAL OF CANCER

Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials

(2012) Guru Sonpavde et al.   EUROPEAN UROLOGY

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

(2012) Christophe Massard et al.   INVESTIGATIONAL NEW DRUGS

Recent Advances in Treatment of Advanced Urothelial Carcinoma

(2012) Jenny J. Kim   Current Urology Reports

Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients

(2011) Carlos Pérez-Ruixo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]

(2010) P. Albers et al.   ANNALS OF ONCOLOGY

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

(2010) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines

(2009) Juan F.M. Leal et al.   BIOCHEMICAL PHARMACOLOGY

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma

(2009) David J. Vaughn et al.   CANCER

Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial Carcinoma

(2009) T. Suyama et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Zalypsis (PM00104) is a potent inducer of  -H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition

(2009) J. Guirouilh-Barbat et al.   MOLECULAR CANCER THERAPEUTICS

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

(2008) E. M. Ocio et al.   BLOOD

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update

(2007) J. Douglas Rizzo et al.   JOURNAL OF CLINICAL ONCOLOGY